Caribou Prepares To Unveil Data On PD-1 Knock Out CAR-T
Also Uses Immune Cloaking
Executive Summary
Proof of concept for Caribou’s gene-editing tweaks is just around the corner, but competition is intense in the allogeneic CAR-T field.
You may also be interested in...
CRISPR Therapeutics Moves Into Off-The-Shelf CAR-T Lead, But Durability Test Awaits
Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.
Sanofi Abandons Oral SERD Breast Cancer Drug As Pipeline Woes Mount
The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.
Beam Therapeutics’ Base-Edited CAR-T Placed On Hold
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.